Shield Therapeutics plc (LON:STX – Get Free Report) passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of GBX 5.17 and traded as low as GBX 4.40. Shield Therapeutics shares last traded at GBX 4.50, with a volume of 2,223,858 shares trading hands.
Shield Therapeutics Price Performance
The firm has a market capitalization of £51.03 million, a PE ratio of -4.77 and a beta of 1.77. The company has a debt-to-equity ratio of -146.28, a quick ratio of 2.16 and a current ratio of 0.75. The business’s 50 day moving average is GBX 5.14 and its two-hundred day moving average is GBX 6.66.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
See Also
- Five stocks we like better than Shield Therapeutics
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
